About the Editor-In-Chief
The Center for Drug Addiction Policy was started by David Aden, who serves as its editor-in-chief. By trade, Mr. Aden is a technologist and writer, primarily covering high tech. He has had a long term interest in drugs and drug abuse, initially kicked off by his own encounters with drugs and drug abuse among his friends as a teenager, reinforced later by his close friendship with several people who worked in drug education and rehabilitation.
Over the last several years he’s taken an active interest in drug abuse policy including the unintended consequences of marijuana law liberalization and the tragedy surrounding the opioid crisis. His areas of interest include both illegal and legal drug abuse, particularly the outsized explosion in prescription drug use that targets vulnerable and minority market groups such as children, the elderly, the military, economically challenged communities and those suffering loss or other real-life problems.
In the early part of 2017, he began to look into the political, financial and regulatory impact of a seemingly new breed of drug addiction solutions that were making their way into prominence with policy makers and governments grouped under the term Medication-Assisted Treatment (MAT). Mr. Aden noticed that although it seemed likely that MAT would have a legitimate place in treatment and recovery options, it also was clear it came with dangers that had not been fully explored. Mr. Aden recognized that our history of drug abuse and drug policy has been marred by tragedies resulting from “unintended consequences” and he concluded we would be better served by more carefully examining the troubling insistence that MAT is the full solution to drug addiction.
He founded the Center for the Study of Drug Addiction Policy as a means to bring together data on drug policy, to examine marketing claims that addiction is fully explained as a physical disease and to explore the growing policy emphasis on MAT. The Center’s mandate is to critically examine current trends so as to assist the public debate, to educate and to advocate for policies that help alleviate the ongoing drug crisis while minimizing unintended consequences.